JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Breast Cancer-Basic and Clinical Research is a premier open access journal published by SAGE Publications Ltd, dedicated to advancing the understanding and treatment of breast cancer through a comprehensive approach that integrates basic and clinical research findings. Since its inception in 2008, this journal has aimed to serve as a vital platform for researchers, healthcare professionals, and students in the fields of oncology and cancer research, providing them with timely access to significant new research, clinical trials, and innovative methodologies. With its current rankings placing it in the Q3 quartile for Cancer Research and Oncology, it reflects a steady commitment to quality and relevance, ranking #167/404 in Medicine - Oncology and #133/230 in Biochemistry, Genetics and Molecular Biology - Cancer Research as of 2023. The journal is designed to foster dialogue and collaboration across disciplines, enabling advancements in therapeutic strategies and patient care. Researchers and professionals will find it an invaluable resource as it continues to push the frontiers of knowledge in breast cancer research.

The Breast Journal, published by Wiley-Hindawi, is a distinguished Open Access journal dedicated to the fields of internal medicine, oncology, and surgery with a particular focus on breast health and disease. Since its inception in 1995, the journal has become an essential resource for researchers and clinicians, facilitating the dissemination of high-quality research and innovative clinical practices. With an impact factor reflecting robust scholarly influence and a ranking in the Q3 quartile for both internal medicine and oncology, as well as Q2 in surgery, it showcases significant contributions that advance knowledge and improve patient outcomes. Offering unparalleled access to its articles, The Breast Journal aims to support a global audience in exploring the multifaceted challenges and breakthroughs in breast-related health, making it a vital platform for shared learning and scientific discourse.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.

GEBURTSHILFE UND FRAUENHEILKUNDE is a prestigious journal dedicated to the fields of Maternity, Midwifery, Obstetrics, and Gynecology, published by GEORG THIEME VERLAG KG, a reputable publisher known for its commitment to advancing medical knowledge. Established in 1947, the journal has consistently provided a platform for high-quality research and clinical studies that address current challenges and innovations in women's health. With an impact factor positioned in Q2 for Maternity and Midwifery and Q3 in Obstetrics and Gynecology, it ranks among the top journals within its field, further solidified by its Scopus rankings highlighting its influential presence. Although the journal is not open access, it remains an essential resource for academics and practitioners keen to stay informed on the latest evidence-based practices and cutting-edge research, ensuring that all stakeholders in women's healthcare can access critical insights to enhance patient outcomes.

Imagerie de la Femme, published by ELSEVIER MASSON, is a pivotal journal in the field of women’s health and surgical practices, holding an ISSN of 1776-9817 and an E-ISSN of 2214-8485. Established in 2005 and converging through to 2024, this journal is dedicated to disseminating high-quality research and innovative findings that contribute to the understanding and advancement of surgical techniques and imaging modalities specifically tailored to women. Despite its current Q3 ranking in Surgery and Scopus rank of 536/551, the journal is increasingly recognized for its focus on emerging trends and critical issues within the discipline. As a scholarly platform, it offers an essential resource for researchers, healthcare professionals, and students alike, promoting knowledge exchange and fostering advancements in the nuanced realm of female surgical health. With its commitment to enhancing clinical practice and patient outcomes, Imagerie de la Femme plays an important role in shaping future research and educational efforts in this vital area of medicine.

Breast Cancer-Targets and Therapy is a leading journal in the field of oncology, published by DOVE MEDICAL PRESS LTD in New Zealand. Established as an Open Access journal in 2009, it offers a platform for researchers and healthcare professionals to disseminate innovative findings and therapeutic strategies related to breast cancer. With an impressive ranking in the Q2 category of oncology journals as of 2023, and placed at Rank #203/404 in the Scopus database, this journal facilitates the exchange of high-quality research aimed at improving patient outcomes and advancing clinical practices. Covering a wide array of topics from basic research to clinical trials, Breast Cancer-Targets and Therapy plays a crucial role in bridging the gap between scientific discovery and practical application. Researchers, professionals, and students alike will find the journal a valuable resource for the latest advancements and best practices in breast cancer treatment.

Revista de Senologia y Patologia Mamaria, published by ELSEVIER, serves as a vital resource for researchers and practitioners in the fields of obstetrics, gynecology, oncology, and radiology. With its ISSN 0214-1582 and E-ISSN 1578-1399, the journal's scope encompasses the latest advancements and multidisciplinary approaches to breast pathology and senology. Despite its current Q4 ranking across various categories, the journal continues to contribute significantly to the academic discourse, offering a platform for rigorous peer-reviewed articles, case studies, and clinical trials. Its ongoing commitment to distributing knowledge that advances the field is essential, especially given the increasing relevance of breast health in patient care. Situated in Spain with accessible research from 2012 to 2024, the journal invites contributions that further the understanding and treatment of breast-related diseases, making it an indispensable tool for students and healthcare professionals alike, eager to enhance their expertise in this specialized area.